Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- SHIRE PLC - FDA Approval of prodrug VYVANSE for treatment of ADHD.
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSEao lisdexamfetamine dimesylate as a Novel Treatment for ADHD Basingstoke, U.K., Philadelphia, PA and Radford, VA - FEBRUARY 23, 2007 - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ)...
- Research articles 2007-02-26
- New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD.
- BASINGSTOKE, England, PHILADELPHIA and RADFORD, Virginia, December 22 /PRNewswire/ -- - Launch Expected Q2 2007 New River Pharmaceuticals Inc. (Nasdaq: NRPH) and its collaborative partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug...
- Research articles 2006-12-22
- Shire's Big Gamble on ADHD Drug Vyvanse
- One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...
- Blog posts 2008-09-04
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- The Pfizer-Shire Deal Worst-Case Scenario
- Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...
- Blog posts 2009-01-07
Additional Resources
- Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults.
- PHILADELPHIA, Pennsylvania, June 29 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has submitted a supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA for VYVANSETM (lis PHILADELPHIA, Pennsylvania, June 29 /PRNewswire/...
- Research articles 2007-06-29
- Shire in a spin over Vyvanse.
- Shires shares have plummeted after high-profile brokers downgrade them on concerns customers aren't switching to its new ADHD drug, Vyvanse Richard Hemming First it was US-based broker Sanford C. Bernstein, then it was Goldman Sachs. Shire's share price has fallen off a...
- Research articles 2008-02-06
- Shire Q4: Bad News Lurks Behind the Good News
- Shire revealed its Q4 2008 results today in a press release that uses a cunning new transparency trick: It gives so much information, in so many different forms, that it's difficult to figure out quickly what exactly is going on at this company. Here's Shire's official take...
- Blog posts 2009-02-19
- Shire plc Q3 2007 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you. We will now begin the question and answer session. [Operator Instructions]. Your first question comes from Brian White from Deutsche Bank. Please ask your question. Brian White - Deutsche Bank AG London Good afternoon....
- Earnings calls 2007-11-03
- Albany Molecular Research, Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator instructions We will go first to Russ Silvestri and SKIRITAI Capital. Russ Silverstri -- SKIRITAI Capital Hi, congratulations. Actually I have four questions. One is Vyvanse being second sourced by anyone? Mark Frost Yes, this is Mark Frost, we are...
- Earnings calls 2008-08-30
- Albany Molecular Research, Inc. Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instruction And we'll take our first question from Amy Stevens with Susquehanna Financial. Amy Stevens Yes, good morning guys. Thanks for taking the question. I just wanted to follow-up a little bit on the DEA quota situation with regard to Vyvanse...
- Earnings calls 2008-02-11
- Shire CEO: Government Probes Are Normal
- Another day, another subpoena. And the latest was sent to Shire last month by the US Department of Health and Human Services Office of Inspector General, which is working with the US Attorney in Philadelphia. The focus of their interest is the sales and marketing practices for three ADHD drugs...
- News items 2009-10-30
- Shire plc Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions. And we have our first question from Gary Nachman. Please go ahead. Gary Nachman – Leerink Swann Hi, thank you. First, for Sylvie, a few on REPLAGAL. What is your share of the market been in Europe? And how has that improved since Genzyme had...
- Earnings calls 2009-11-01
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine dimesylate) as a Novel Treatment for ADHD.
- BASINGSTOKE, England, Philadelphia, PHILADELPHIA and Radford, VIRGINIA, February 23 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the BASINGSTOKE, England, Philadelphia, PHILADELPHIA and Radford, VIRGINIA, February...
- Research articles 2007-02-23
- SHIRE PLC - New River and Shire Receive Approvable Ltr for VYVANSE.
- New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSEao lisdexamfetamine dimesylate for the Treatment of ADHD Launch Expected Q2 2007 Basingstoke, U.K., Philadelphia, PA and Radford, VA - DECEMBER 21, 2006 - New River Pharm New River Pharmaceuticals and Shire...
- Research articles 2006-12-22
- Shire CEO Compensation Report Successfully Conceals CEO Compensation
- Shire, the British company that markets Adderall and Vyvanse, has produced a compensation report for its senior executives that is all but impossible to understand. The disclosure, starting on page 52 of the annual report, describes the compensation of just three of its top executives -- former...
- Blog posts 2009-03-25
- GSK Q1: £450 Million in Generic Damage to CNS Category
- GlaxoSmithKline's Q1 2009 results should scare the living daylights out of companies that are heavily dependent on CNS products such as Shire Vyvanse and Adderall, Forest Labs Lexapro and Eli Lilly Cymbalta. Generics shaved off 53 percent of GSK's CNS drug sales, which were down £450 million....
- Blog posts 2009-04-23
- Shire Q1: The Big Fight Against Teva's Generics Begins
- Shire, the maker of ADHD drugs Adderall XR and Vyvanse had an excellent Q1 but now faces a challenge: It's two top products are threatened by a generic that Teva brought to market on April 2. The company is also persisting in the U.S with its Daytrana ADHD patch, which...
- Blog posts 2009-05-04
- Shire CEO Says His ADHD Market Share Dropped 10 Percentage Points
- Shire's grip over the ADHD market with Adderall XR and its replacement drug, Vyvanse, appears to be weakening due to generic competition, according to CEO Angus Russell. In an interview with Reuters Russell said Shire's share had slipped from 26 percent to 16 percent. by Jim Edwards
- Blog posts 2009-06-05
- Shire Q2: The Party's Over as Teva's Generics Decimate Adderall
- For months, Shire has been trying to defy gravity by jacking up the price of Adderall XR in order to encourage users to switch to its cheaper, new ADHD drug, Vyvanse. This quarter it came down to earth as sales collapsed in the face of generic competition. by Jim Edwards
- Blog posts 2009-08-05
- << Previous
- page 1 of 1
- Next >>
